Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based...

TUESDAY, Aug. 12, 2024 -- An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and...

A new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer....

Therma Bright’s (TSXV:THRM) Digital Cough Technology is being considered for a new chronic cough drug, U.S.-based clinical trial.

The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares...

Pharmadrug Inc (CSE: PHRX) has received approval for its majority owned joint venture, Sairiyo Therapeutics, to process with a Phase 1 clinical study...

Highlights: Tirzepatide significantly lowers hospitalization and death risks in heart failure patients The drug

The majority of cancer patients involved in a landmark Perth clinical trial remain in remission years later after a breakthrough treatment that...

The FDA approves a new glioma therapy for the first time in decades, offering renewed hope for patients with this challenging brain cancer.

The 3D Urology and Prostate Clinics present their advanced 3D Targeted Therapy, offering effective and personalized prostate care solutions for...